Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. - Wikidata - awgldk - TriplyDB

Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial.

Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial.

http://www.wikidata.org/entity/Q38009430

about

A Clearer View of Evidence in Treating Macular Degeneration: Off-Label Policies and Independent Research Systemic safety of bevacizumab versus ranibizumab for neovascular age-related macular degeneration Anti-vascular endothelial growth factor for neovascular age-related macular degeneration Anti-vascular endothelial growth factor for choroidal neovascularisation in people with pathologic myopia Treatment schedules for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review Guidelines for the Management of Wet Age-Related Macular Degeneration: Recommendations from a Panel of Greek Experts Management of Neovascular Age-related Macular Degeneration: A Review on Landmark Randomized Controlled Trials Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a systematic review and meta-analysis Treatment as Required versus Regular Monthly Treatment in the Management of Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis Parainflammation, chronic inflammation, and age-related macular degeneration Management of neovascular age-related macular degeneration: current state-of-the-art care for optimizing visual outcomes and therapies in development Comparative safety and tolerability of anti-VEGF therapy in age-related macular degeneration Optical coherence tomography for the diagnosis of neovascular age-related macular degeneration: a systematic review The safety of intravitreal bevacizumab monotherapy in adult ophthalmic conditions: systematic review The design and implementation of a study to investigate the effectiveness of community vs hospital eye service follow-up for patients with neovascular age-related macular degeneration with quiescent disease.Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials Evidence-based review of diabetic macular edema management: Consensus statement on Indian treatment guidelines Early detection of age related macular degeneration: current status Ranibizumab for age-related macular degeneration: a meta-analysis of dose effects and comparison with no anti-VEGF treatment and bevacizumab Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema Vascular Endothelial Growth Factor Inhibitors for Diabetic Retinopathy.SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB.Switch of anti-VEGF agents is an option for nonresponders in the treatment of AMD 24-month clinical outcomes of a treat-and-extend regimen with ranibizumab for wet age-related macular degeneration in a real life setting.A Systematic Review of the Treat and Extend Treatment Regimen with Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration.Fellow eye effect of unilateral intravitreal bevacizumab injection in eyes with diabetic macular edema Morphological changes in spectral domain optical coherence tomography guided bevacizumab injections in wet age-related macular degeneration, 12-months results.How many people in England and Wales are registered partially sighted or blind because of age-related macular degeneration?Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration.Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial.Drug treatment of macular oedema secondary to central retinal vein occlusion: a network meta-analysis.Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA).Predictive factors for non-response to intravitreal ranibizumab treatment in age-related macular degeneration Sustained visual acuity loss in the comparison of age-related macular degeneration treatments trials.Clinical utilization of anti-vascular endothelial growth-factor agents and patient monitoring in retinal vein occlusion and diabetic macular edema.VEGFA and VEGFR2 gene polymorphisms and response to anti-vascular endothelial growth factor therapy: comparison of age-related macular degeneration treatments trials (CATT).Acute sterile endophthalmitis following intravitreal bevacizumab: case series.Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors.Bevacizumab and ranibizumab for neovascular age-related macular degeneration: an updated meta-analysis of randomised clinical trials.

P2860

Q24193409-611270F5-5001-4830-A426-F80841D33EED Q24193614-0376DAE0-258E-4ACE-A9C1-967CA117C240 Q24194251-B34B1C23-753D-4EAB-9E78-385B03596870 Q24194332-2574A7F0-6B2D-4194-B794-9618D04B25C0 Q26472033-8117E49F-BDF8-4C64-ABBC-800FE5CFBD05 Q26744068-73A4A483-1D45-4532-836C-3B60876B494C Q26749615-10797339-28D4-49F0-9164-A672C7C43C91 Q26767095-30454263-DA21-4F1D-9CEC-72CF27F5D467 Q26785646-19BB524F-786A-4CD2-A3D7-C4B214A88F1F Q26787156-25292B85-01A7-4289-A832-C50FEE61BAD5 Q26796268-9D9DA49C-31D2-4604-8486-F1852FB7BAA7 Q26824335-68F46628-2036-4DBE-B080-E978180358BB Q26852289-74D952A7-BE4D-4A44-9BC7-E4BC5415C047 Q27002615-B08521AB-1A44-434A-A17D-B4F0364A3E4B Q27013836-C8C63171-E4F5-4555-9A60-B36F39959B61 Q27324293-73FBA5EC-479E-4D2E-AECE-C026CA0C26DE Q28049700-EFFD0315-4815-4BFA-9631-BEFFDEAF2A31 Q28075473-8803C7CD-2A32-4E37-B678-1ACD112D136A Q28076117-A14712AA-23FF-42E1-B3C2-B215919ECA43 Q28236004-72816C60-DA8F-4E8B-BDB7-D1C8C8347641 Q28292764-883E71B7-D906-4EB2-A2AD-F3A5AB29211F Q30244247-31084EFE-709D-403C-82D4-21EAC87DC331 Q30490738-E066BB08-B6DD-4733-90C6-086B8B12317C Q33595182-39200AAA-ED41-4A08-831A-693E913FF0B4 Q33612736-BA0A9EB8-F6F2-48B1-BA21-455B560CC816 Q33740162-B998F1CC-B190-4A0F-8484-E3D9FC563DDE Q33759212-4C5EEC12-9D6A-491E-8F8E-6F853974B7A5 Q33785965-CC2725E2-FBAD-47AB-AC9B-CF5E16906830 Q33891120-35C47CDF-E2B1-460F-8F1C-3AAF516D22EB Q33944980-F19D18DF-AD80-4CF3-9CDD-D363AA008C3E Q33995880-072AD26C-F873-40FF-878E-2C4099D48097 Q33995887-F3AFD991-196D-4DA1-B3AC-895BDF95ABA6 Q34092454-E267F620-0B0A-4AC3-AB7A-A30BA372706F Q34092569-95CE7177-84FE-45F7-A478-18E6964AEE9A Q34117752-A5C12D0A-F3CC-40B3-A806-4F1EAF1FE42A Q34139793-AD1648A6-0F57-4A2F-AC8C-9413BA7847CF Q34170457-CDE13E23-B179-479B-BE7B-7A1566128AAB Q34182273-B813B92C-E95C-4B4D-BD1B-71B186995D2B Q34253393-39321878-8558-43EE-AC92-1678AF420A62 Q34271021-8DC9E11D-E9B4-489C-AA5A-55DE453A71E9

P2860

Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial.

http://www.wikidata.org/entity/Q38009430

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Ranibizumab versus bevacizumab ...... rom the IVAN randomized trial.

@en

type

label

Ranibizumab versus bevacizumab ...... rom the IVAN randomized trial.

@en

prefLabel

Ranibizumab versus bevacizumab ...... rom the IVAN randomized trial.

@en

P1433

Q38009430-62970EE8-5007-49B4-8EDE-7B8AF80F3B0B

P1476

Q38009430-F2451F7C-2367-48DC-A249-9F616E0C9B2A

P2093

Q38009430-2BFE8B95-A887-4B46-8B17-D0A0A4091ADC

Q38009430-47B10704-A5D4-493A-9D98-1957F4F2CAD1

Q38009430-7F2DDFDB-6041-4412-B5A1-585B9E162EF6

Q38009430-D8D6C30E-2A8D-416D-A847-845C2823C0AE

Q38009430-DBB91D83-43A7-481C-8BF9-075079FEA1C5

Q38009430-DDA1617C-79F3-4447-B610-BBEF9F4354CC

Q38009430-E1C28DF7-128A-4FE5-B399-89F2A5393C04

Q38009430-ED81E425-4131-4A10-90F3-942CAE4C72F9

P304

Q38009430-0153F745-0B5B-4FC5-A0F1-21271DE950F2

P31

Q38009430-830E2FAF-2080-451A-92D2-7FF95CC9952D

P356

Q38009430-9E14300D-7A7F-4527-9BB7-F061DF2C264B

P433

Q38009430-8E86D597-DE78-488F-9C11-B6A40ED4C969

P478

Q38009430-20486E84-9557-4457-9DCB-70E881CDCDBE

P577

Q38009430-0B7108E1-A3F3-469E-A814-986851B9AF9B

P5875

Q38009430-F04FDC5D-844C-4CE9-8C8B-8C83228D2DE5

P698

Q38009430-F255ECE7-7B49-4D07-AA92-D1C7284AEEA5

P921

Q38009430-6F3BC99F-F196-4714-80CB-D4D42475D990

P356

J.OPHTHA.2012.04.015

P1433

P1476

Ranibizumab versus bevacizumab ...... rom the IVAN randomized trial.

@en

P2093

Andrew J Lotery

http://www.w3.org/2001/XMLSchema#string

Barnaby C Reeves

http://www.w3.org/2001/XMLSchema#string

Chris A Rogers

http://www.w3.org/2001/XMLSchema#string

IVAN Study Investigators

http://www.w3.org/2001/XMLSchema#string

Sarah Wordsworth

http://www.w3.org/2001/XMLSchema#string

Simon P Harding

http://www.w3.org/2001/XMLSchema#string

Susan M Downes

http://www.w3.org/2001/XMLSchema#string

Usha Chakravarthy

http://www.w3.org/2001/XMLSchema#string

P304

1399-1411

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.OPHTHA.2012.04.015

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

119

http://www.w3.org/2001/XMLSchema#string

P577

2012-05-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

224947713

http://www.w3.org/2001/XMLSchema#string

P698

22578446

http://www.w3.org/2001/XMLSchema#string

P921